Adamis Pharmaceuticals Jumps

Adamis Pharmaceuticals said on Thursday that the US Food and Drug Administration (FDA) has accepted for review its refiled new drug application for its epinephrine pre-filled syringe product candidate for the emergency treatment of anaphylaxis, a rapid-onset allergic reaction.

The company refiled its application on Dec. 15 to address the issues raised by the FDA in its response in June, Adamis said. The FDA indicated that it considered the resubmission to be a complete response, the company said. The shares rose more than 10% in in early trading on Thursday.

Leave a Comment